Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors

Journal of Lipid Research

Volumn 37, Issue 6, 1996, Pages 1316-1324

  Bohnet, Karin ^a   Pillot, Thierry ^b   Visvikis, Sophie ^a   Sabolovic, Nicole ^b   Siest, Gérard ^a,b  

^a Centre de Medecine Preventive   (France)

^b INSERM   (France)

Author keywords

apolipoprotein E concentration; apolipoprotein E polymorphism; binding; hepatic receptors; very low density lipoproteins

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CELL SURFACE RECEPTOR; CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CELL STRAIN HEPG2; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

APOLIPOPROTEINS E; CARCINOMA, HEPATOCELLULAR; CELL LINE; GENOTYPE; HUMANS; KINETICS; LIPOPROTEINS, VLDL; LIVER NEOPLASMS; RECEPTORS, LDL; TUMOR CELLS, CULTURED;

EID: 0029896263     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Rall, S. C., Jr., K. H. Weisgraber, and R. W. Mahley. 1982. Human apolipoprotein E. The complete amino acid sequence. J. Biol. Chem. 257: 4171-4178.
2. Sing, C. F., and J. Davignon. 1985. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am. J. Hum. Genet. 37: 268-285.
3. Boerwinkle, E., S. Visvikis, D. Welsh, J. Steinmetz, S. M. Hanash, and C. F. Sing. 1987. The use of measured genotype information in the analysis of quantitative phenotypes in men. II. The role of apolipoprotein polymorphism in determining levels, variability and covariability of cholesterol, beta-lipoprotein and triglycerides in a sample of unrelated individuals. Am. J. Hum. Genet. 27: 567-582.
4. Davignon, J., R. E. Gregg, and C. F. Sing. 1988. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 8: 1-21.
5. Strittmatter, W. J., A. M. Saunders, D. Schmechel, M. Pericak-Vance, J. Enghild, G. S. Salvesen, and A. D. Roses. 1993. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late onset familial Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 90: 1977-1981.
6. Lucotte, G., F. David, S. Visvikis, B. Leininger-Muller, G. Siest, and M. C. Babron. 1993. Apolipoprotein-E-ε4 allele and Alzheimer's disease. Lancet. 342: 1309.
7. Lucotte, G., S. Visvikis, B. Leininger-Muller, F. David, S. Berriche, and S. Reveilleau. 1994. Association of apolipoprotein E allele 4 with late-onset sporadic Alzheimer's disease. Am. J. Med. Genet. 54: 286-288.
8. Cardin, A. D., T. L. Bowlin, and J. L. Krstenansky. 1988. Inhibition of lymphocyte proliferation by sythetic peptides homologous to human plasma apolipoproteins B and E. Biochem. Biophys. Res. Commun. 154: 741-745.
9. Handlemann, G. E., J. K. Boyles, K. H. Weisgraber, R. W. Mahley, and R. E. Pitas. 1992. Effects of apolipoprotein E, β-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J. Lipid Res. 33: 1677-1688.
10. Beisiegel, U. 1995. Receptors for triglyceride-rich lipoproteins and their role in lipoprotein metabolism. Curr. Opin. Lipidol. 6:117-122.
11. Javitt, N. B. 1990. HepG2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J. 4: 161-168.
12. Hixson, J. E., and D. T. Vernier. 1990. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31: 545-548.
13. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
14. Scatchard, G. 1949. The attraction of proteins for small molecules and ions. Ann. NY Acad. Sci. 51: 660-672.
15. Dashti, N., and G. Wolfbauer. 1986. Studies on the binding and degradation of human very-low-density lipoproteins by human hepatoma cell line HepG2. Biochim. Biophys. Acta. 875: 473-486.
16. Chappell, D. A. 1993. Low density lipoprotein receptors bind and mediate cellular catabolism of normal very low density lipoproteins in vitro. J. Biol. Chem. 268: 25487-25493.
17. Bradley, W. A., and S. H. Gianturco. 1986. ApoE is necessary and sufficient for the binding of large triglyceride-rich lipoproteins to the LDL receptor; apoB is unnecessary. J. Lipid Res. 27: 40-48.
18. Krul, E. S., M. J. Tikkanen, and G. Schonfeld. 1988. Heterogeneity of apolipoprotein E epitope expression on human lipoproteins: importance for apolipoprotein E function. J. Lipid Res. 29: 1309-1325.
19. Lund-Katz, S., K. H. Weisgraber, R. W. Mahley, and M. C. Phillips. 1993. Conformation of apolipoprotein E in lipoproteins. J. Biol. Chem. 268: 23008-23015.
20. Eisenberg, S., G. Friedmann, and T. Vogel. 1988. Enhanced metabolism of normolipidemic human plasma very low density lipoprotein in cultured cells by exogenous apolipoprotein E-3. Arteriosclerosis. 8: 480-487.
21. Kowal, R. C., J. Herz, J. L. Goldstein, V. Esser, and M. S. Brown. 1989. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA. 86: 5810-5814.
22. Ji, Z. S., S. Fazio, and R. W. Mahley. 1994. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J. Biol. Chem. 269: 13421-13428.
23. 2-macroglobulin receptor is induced by the C-terminal domain of lipoprotein lipase. J. Biol. Chem. 269: 18001-18006.
24. Weisgraber, K. H., T. L. Innerarity, and R. W. Mahley. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257: 2518-2521.
25. Kowal, R. C., J. Herz, K. H. Weisgraber, R. W. Mahley, M. S. Brown, and J. L. Goldstein. 1990. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 265: 10771-10779.
26. Mann, W. A., N. Meyer, W. Weber, S. Meyer, H. Greten, and U. Beisiegel. 1995. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. J. Lipid Res. 36: 517-525.
27. Demant, T., D. Bedford, C. J. Packard, and J. Shepherd. 1991. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipidemic subjects. J. Clin. Invest. 88: 1490-1501.
28. Gregg, R. E., and H. B. Brewer. 1988. The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B containing lipoproteins in humans. Clin. Chem. 34B: 28B-32B.
29. Wilson, H. M., J. C. Patel, D. Russel, and E. R. Skinner. 1993. Alterations in the concentration of an apolipoprotein E-containing subfraction of plasma high density lipoproteins in coronary heart disease. Clin. Chim. Acta. 220: 175-187.
30. Yamada, N., I. Inoue, M. Kawamura, K. Harada, Y. Watanabe, H. Shimano, T. Gotoda, M. Shimada, T. Kohzaki, T. Tsukada, M. Shiomi, and Y. Yazaki. 1992. Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. J. Clin. Invest. 89: 706-711.
31. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258: 468-471.